China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.
China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.
Sells meters cheaply and earns on the test strips patients buy again and again, so every installed meter feeds repeat revenue. Most sales are in China through pharmacies and distributors, with exports a smaller part. It has added its own continuous glucose monitor, which reads sugar through a sensor worn on the skin.
In one line: China's LifeScan/Ascensia for glucose meters.
Moat: narrow (brand, distribution, installed base). Leading domestic brand with wide pharmacy distribution and installed meter base.
Headquarters: Changsha, Hunan, China · Founded: 2002 · Employees: 5,010
Size Sinocare (300298.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.45B, the 1559th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.51 on 18 Nov 2026.
Performance Over six months the shares gained 4.0%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 7.3% over the last twelve months (peer median +12.1%); the operating margin is 5.7% (peer median 8.2%).
Valuation It trades at 21.5× forward earnings against a peer median of 27.0× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (6.1% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.05B | CN¥4.64B | CN¥4.42B | CN¥4.04B | CN¥3.93B |
| Revenue growth | — | +5% | +9% | +3% | — |
| Gross profit | CN¥2.70B | CN¥2.14B | CN¥2.29B | CN¥2.03B | CN¥1.96B |
| EBITDA | n/a | CN¥396M | CN¥610M | CN¥548M | CN¥565M |
| Net income | CN¥253M | CN¥92.6M | CN¥326M | CN¥284M | CN¥447M |
| Free cash flow | CN¥392M | CN¥408M | CN¥446M | CN¥390M | CN¥366M |
| Capital expenditure | CN¥147M | CN¥199M | CN¥187M | CN¥347M | CN¥320M |
| Total debt | CN¥1.09B | CN¥960M | CN¥959M | CN¥1.22B | CN¥1.60B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sinocare 300298.SZ | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% |
| Andon Health 002432.SZ | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300298.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.6% | -1.6% | 6th highest of 21 |
| 6-month return | +4.0% | -8.9% | 7th highest of 21 |
| Distance from 52-week high | -13.8% | -30.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +7.3% | +12.1% | 9th lowest of 21 |
| Operating margin | 5.7% | 8.2% | 9th lowest of 21 |
| Forward P/E | 21.5× | 27.0× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 9.5% | 18.4% | 5th least demanding of 15 |
| Growth delivered (Del g) | +18.3% | +15.6% | 7th highest of 15 |
| Hurdle (Req g minus delivered) | -8.8 pp | -3.8 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | +2.2 pp | -1.1 pp | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |